NCT05305365: Study Assessing QBS72S For Treating Brain Metastases of Triple Negative Breast Cancer

NCT05305365
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain, Leptomeningeal Disease 
Additional Notes: 
Exclusions: Patients with tumors in the brainstem or spinal cord parenchyma
https://ClinicalTrials.gov/show/NCT05305365

Comments are closed.

Up ↑